Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 4,151 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,151 shares of Hims & Hers Health stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $45.14, for a total transaction of $187,376.14. Following the completion of the sale, the insider now owns 166,134 shares of the company’s stock, valued at approximately $7,499,288.76. The trade was a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 14th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.72, for a total value of $92,937.92.
• On Monday, March 31st, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.77, for a total value of $89,863.72.
• On Tuesday, February 18th, Soleil Boughton sold 4,152 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88.
• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $27.24 on Friday. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The firm has a market cap of $6.05 billion, a PE ratio of 61.91 and a beta of 1.65. The firm’s fifty day moving average is $37.59 and its 200-day moving average is $30.56.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Crewe Advisors LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. boosted its position in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health during the 4th quarter worth about $38,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on HIMS shares. Piper Sandler boosted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th. Truist Financial lowered their price target on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating for the company in a report on Thursday, April 10th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $38.25.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.